Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
domvanalimab + zimberelimab + etrumaadenant + quemliclustat + sacituzumab govitecan
- Development stage
- Unknown
- Lead developer
- Arcus Biosciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This entry refers to a clinical development platform (specifically the **EDGE-Lung** and **VELOCITY-Lung** Phase 2 trials) led by **Gilead Sciences** in collaboration with **Arcus Biosciences**. The platform evaluates various combinations of immunotherapies and targeted agents for the treatment of non-small cell lung cancer (NSCLC). The regimen includes **domvanalimab** (an Fc-silent anti-TIGIT monoclonal antibody), **zimberelimab** (an anti-PD-1 monoclonal antibody), **etrumaadenant** (a dual A2A/A2B adenosine receptor antagonist), **quemliclustat** (a small molecule CD73 inhibitor), and **sacituzumab govitecan** (a TROP-2 directed antibody-drug conjugate). The strategy aims to target multiple immunosuppressive pathways (adenosine, TIGIT, PD-1) and deliver cytotoxic payloads (via ADC) to enhance anti-tumor activity in NSCLC.
- Brand names
- Trodelvy
- Other names
- EDGE-LungVELOCITY-LungMedivir/Gilead Sciences-TIGIT-PD-1-A2A/A2B adenosine-TROP-2-CD73-monoclonal antibody-ADC-small molecule-NSCLC
02
Targets
ADORA2A (Adenosine A₂A Receptor)PDCD1 (Programmed cell death protein 1 receptor)NT5E (Cluster of Differentiation 73)ADORA2B (Adenosine A2B receptor)ADORA1 (Adenosine receptor A1 subtype)TIGIT (T cell immunoreceptor with Ig and ITIM domains)TOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)
Beyond the preview
Go deeper on domvanalimab + zimberelimab + etrumaadenant + quemliclustat + sacituzumab govitecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on domvanalimab + zimberelimab + etrumaadenant + quemliclustat + sacituzumab govitecan.